Cannabis - Forensic Toxicology (Lecture Notes) PDF
Document Details
Uploaded by StatelyAmber
University of Alberta
Graham R. Jones, Ph.D.
Tags
Summary
These notes provide an overview of forensic toxicology related to cannabis, covering different cannabinoids, measurement methods, pharmacokinetics, and effects. It also discusses the interpretation of results in legal contexts and the differences between the analysis of cannabis and alcohol intoxication.
Full Transcript
1 Cannabis - Forensic Toxicology Graham R. Jones, Ph.D. Former Chief Toxicologist, OCME & Clinical Professor, U of A Faculty of Medicine and Dentistry Edmonton, Alberta, Canada What do most forensic labs measure? • Delta-9-tetrahydrocannabinol (∆9-THC) • Highly lipid soluble • Usually measured i...
1 Cannabis - Forensic Toxicology Graham R. Jones, Ph.D. Former Chief Toxicologist, OCME & Clinical Professor, U of A Faculty of Medicine and Dentistry Edmonton, Alberta, Canada What do most forensic labs measure? • Delta-9-tetrahydrocannabinol (∆9-THC) • Highly lipid soluble • Usually measured in whole blood • Majority of the research was conducted in serum or plasma • THC blood:plasma ratio ~0.5 - 0.6 • 11-Hydroxytetrahydrocannabinol (11-OH-THC) • Pharmacologically “active” • Concentrations are higher after oral ingestion (first pass effect) • 11-Carboxytetrahydrocannabinol (THC-COOH) • Inactive metabolite • Forms water soluble glucuronide metabolite • Majority present as the glucuronide • Most labs measure the unconjugated THC-COOH (in blood) • Most urine testing labs (workplace) measure the total THC-COOH • Most forensic labs do NOT measure cannabidiol (CBD) ‘Emerging’ in the last couple of years* • Delta-8-tetrahydrocannabinol (∆8-THC) • Low concentrations natural present in Cannabis • Slightly less potent than ∆9-THC abd similar side-effects than ∆9-THC • Challenging to separate from ∆9-THC analytically • Delta-10-tetrahydrocannabinol (10-THC) • Positional isomer of ∆9-THC not usually present in Cannabis • Less potent than ∆9-THC(?) • Tetrahydrocannabiphorol (THC-P) • Much more potent (~30x) than ∆9-THC; not present in Cannabis • O-Acetyl-delta-9-tetrahydrocannbinol (THC-O) • Up to 3 x more potent than ∆9-THC; not present in Cannabis • May have hallucinogenic effects at high doses Other “Cannabis” Cannabinoids • Over 100 cannabinoids naturally present in cannabis • Cannabidiol (CBD) • Can be up to 40% of cannabis plant extract • Has been studied to treat anxiety, cognition, movement disorders, pain and epilepsy disorders • Little if any psychoactivity • May modify the effects of THC if both are present • Legal in the USA (cannabis extracts are not) • Cannabinol (CBN) • Mildly psychoactive, but present in only small amounts in cannabis • Is a metabolite of delta-9-THC Effects of Δ-9-Tetrahydrocannabinol • Psychoactive effects include • a state of relaxation, perhaps euphoria • facility for philosophical thinking, introspection • anxiety and paranoia • increase in heart rate and hunger, reddening of eyes • reduces nausea and vomiting • impaired motor skills; • Impaired judgment of time and distance Note: unless otherwise stated, any reference to “THC” in this lecture refers to ∆9-THC Interpretation...not as ‘easy’ as with alcohol • For alcohol (ethanol) there is a generally ‘direct’ correlation between blood concentration and “effect” (e.g. impairment) • Ethanol: can estimate “dose” from a blood level and can estimate a blood level from a dose • For THC, the correlation Data from: https://www.infrastructure.gov.au/roads/safety/publications/1997/pdf/Speed_Risk_1.pdf between blood level and “effect” is very poor except in the very early stages of smoking Pharmacokinetics of THC & metabolites • The “peak” ∆9-THC represents cessation of smoking • Note, the “research” cigarette only 3.55% THC • In most people, duration of the ‘high’ lasts 2 – 6 hours, i.e. much longer than the blood THC concentration is elevated Huestis MA, Henningfield JE, Cone EJ. 1992 Delta-9-THC • Short distribution half- life • Long elimination halflife resulting in “baseline” blood THC concentrations up to 7 ng/mL after heavy chronic use CH Ashton, Br J Psychiatry, Volume 178: 101-6, 2001 EW Schwilke, EL Larschner, RH Lowe, WD Darwin, MA Huestis, SOFT Abstract 23, NC Oct 2007 8 Cannabis – Forensic / Postmortem Aspects Canadian Criminal Code - Cannabis • Part I of Bill C-46, came into force on June 21, 2018: • an offence for (low-level) THC concentrations of 2 ng/mL to • • • • less than 5 ng/mL, within 2 hours of driving. an offence for higher-level THC concentrations of 5 ng/mL or more, within 2 hours of driving. an offence that recognizes the effects of combined marijuana and alcohol consumption; 50 mg of alcohol per 100 mL blood plus 2.5 ng/mL or more of THC within 2 hours of driving. “per se” limits that have little correlation with “effect or degree of actual impairment”. Recognizes that THC has a short half-life in blood and that it could take police up to 2 hours to get a blood sample drawn. 11 But with THC it can get complicated in civil cases • THC has a relatively short half-life in blood • But a longer half-life in the brain • i.e. where THC has its primary effect related to impairment • And it has a MUCH longer half-life in the body • Lawyers will ask: • What does the blood THC level mean? • Is there a blood alcohol equivalent? • Does a blood concentration of ‘X’ ng/mL mean they were impaired? 12 Delta-9-THC: The Past ‘Wisdom’* • The following used to be held as accepted facts: • THC always drops to near zero a few hours after last smoke • “Blood” THC >2-3 ng/mL consistent with recent use (within 6 h) • You can use THC:THC-COOH ratio to estimate the time of last use • Little postmortem change • …NOT ANY MORE Huestis, M.A and Smith, M.L 2007 13 THC: What we now know … • Baseline blood THC several hours after smoking: • typically < 2 ng/mL in light smokers (<1 after 24 h) • can be > 5 ng/mL in heavy smokers (may be >10) • in one study 1.2 – 5.5 ng/mL 7 days after last use • very high body burden of THC slowly released into blood • Refers to LIVING people! 14 THC Postmortem – It’s More Complex • THC undergoes postmortem redistribution (i.e. can increase after death) • PM femoral blood THC can be MUCH higher in postmortem blood than pre-mortem (‘clinical’) blood • THC concentrates in muscle tissue and may be redistributing postmortem • But much larger effect may be the presence of fat in the postmortem blood drawn 15 Case 1: Aircraft Pilot with THC* • Young commercial pilot flew a small passenger plane into a hillside: “controlled flight into terrain” • Pilot killed on impact or soon after; 2 passengers survived • Pilot toxicology positive for cannabis: • Pleural blood: THC 11.9 ng/mL; carboxy 41.8 ng/mL • Femoral blood: THC 50.1 ng/mL; carboxy 21.6 ng/mL • Pilot could not have been smoking for at least 1 hour before the crash and probably closer to 2 hours • Did the blood THC reflect concentration in flight? • Was the pilot impaired by THC? 16 Case 2: ATV Death with THC* • Middle-aged man involved in an ATV roll-over • Taken to hospital with relatively minor injuries • Includes broken clavicle • Dies from lacerated subclavian vessel and massive bleed • Postmortem toxicology negative except for cannabis: • Antemortem blood THC 14 ng/mL; carboxy 110 ng/mL • Time: 2 hours post-accident • PM femoral blood THC 31 ng/mL; carboxy 19 ng/mL • Time: 68 hours post-accident, after 60 – 66 hours in ICU 17 Case 3: Stabbing victim with THC* • Young man stabbed to death; short survival time • PM Toxicology (blood): • Ethanol, cocaine, levamisole, phenacetin, cannabinoids • Central blood THC 3.5 ng/mL; carboxy 11.8 ng/mL • Femoral blood THC 37.1 ng/mL; carboxy 8.4 ng/mL • Huh? • Elevated femoral blood THC likely due to contamination with “fat” containing sequestered THC from current and past smoking Postmortem blood is not always a reliable sample Remember – THC is very fat soluble!! LEGALIZATION OF CANNABIS Interpretation can be quite complex and may affect both criminal and civil case litigation! SYNTHETIC CANNABINOIDS (AKA CANNABIMIMETICS; AKA “SPICE”, “K2” ETC) 21 “Spice” – Synthetic Cannabinoids • Aka Cannabimimetics • Chemicals impregnated into various dried plant materials • Synthetic chemicals that may or may not be closely related to the structure of delta-9-THC – Interacts with the cannabinoid receptors – Partial agonist activity at the cannabinoid receptor CB1 located mainly in the central nervous system – and the CB2 receptor, mainly in cells of the immune system • Four primary series – JWH (John W. Huffman, funded by NIDA for medical research) – AM (Alexandros Makriyannis, Northeastern University) – CP (research chemists at Pfizer) – HU (Raphael Mechoulam, the Hebrew University) • Many do not have true “THC” effects 22 Cannabimimetic Properties • Similar to Cannabis (hence “…mimetic”), but some may have more intense effect in ability to produce psychosis. • Psychoactive effects include • a state of relaxation, perhaps euphoria • facility for philosophical thinking, introspection • anxiety and paranoia; also • increase in heart rate and hunger, reddening of eyes • reduces nausea and vomiting • impaired motor skills; judging time and distance 23 Adverse effects of synthetic cannabinoids • Psychiatric • Psychosis (new-onset or exacerbation of pre-existing disease), agitation, anxiety, irritability, confusion, aggression, suicidality, memory changes, tolerance, withdrawal, dependence • Cardiovascular • Hypertension, tachycardia, ST-segment changes, chest pain, myocardial infarction, tachyarrhythmia • Neurologic • Generalized seizures, somnolence, brisk reflexes • Gastrointestinal • Nausea, vomiting, anorexia, increased appetite • Other • Hypokalemia, conjunctival injection (‘blood shot’ eyes), hyperglycemia, acute kidney injury, xerostomia (dry mouth), diaphoresis • Ref: Five things to know about synthetic cannabinoids.CMAJ, February 18, 2014, 186(3) 24 * 25 * 26 Cannabimimetic Analysis • Can be difficult! • Very low blood concentrations • Extensively metabolized • Over 200 possible structures • They keep changing as regulations change • Screening methods do not detect all • Need high-end methods for confirmation • e.g. LC/MS/MS • Relatively difficult and time-consuming to develop 27 Metabolism of JWH-18 – Clearance from blood* 28 Prevalence of different cannabimimetics over 3.5 years * 29 Risk Factors for Users • Downside: don’t know what you are getting • May vary from batch to batch even with the same name and label – substance and dose • Toxicity will vary tremendously depending on dose and the individual • For most ‘designer’ drugs little is known about toxicity and longterm effects 30 Canada vs. USA – The Differences • Canada: • Federal drug laws (Controlled Drugs and Substances Act – CDSA) • Specific named substances, but chemically related drugs that may have a similar pharmacological effect are similarly controlled (specific substances do not always have to be named) • USA: • DEA (Drug Enforcement Administration) has “federal” rules, but slow to add new substances • Did have Federal Analogue Act 1986 but sometimes difficult to get a prosecution • e.g. what is an analogue (how similar is it to a scheduled drug) • Stop the Importation and Trafficking of Synthetic Analogues Act of 2017 Individual states can make individual drugs illegal, but that was a slow “ad hoc” process that did not usually address “analogues”